SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Astrazeneca Pharma I - Quaterly Results

30 May 2025 Evaluate
The sales surged to Rs. 4804.80 millions, up 25.39% for the March 2025 quarter as against Rs. 3832.00 millions during the corresponding quarter previous year.The company has announced a 47.54% increase in its profits to Rs . 582.50  millions for the  quarter ended March 2025 compared to Rs. 394.80 millions in the corresponding quarter in the previous year.OP of the company witnessed a marginal growth to 1025.20 millions from 580.50 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 4804.80 3832.00 25.39 17162.90 12955.30 32.48 17162.90 12955.30 32.48
Other Income 161.50 86.60 86.49 406.30 348.00 16.75 406.30 348.00 16.75
PBIDT 1025.20 580.50 76.61 2946.00 2192.50 34.37 2946.00 2192.50 34.37
Interest 6.80 -0.70 -1071.43 14.60 12.00 21.67 14.60 12.00 21.67
PBDT 961.60 581.20 65.45 1963.50 2344.80 -16.26 1963.50 2344.80 -16.26
Depreciation 176.90 37.60 370.48 399.90 149.40 167.67 399.90 149.40 167.67
PBT 784.70 543.60 44.35 1563.60 2195.40 -28.78 1563.60 2195.40 -28.78
TAX 202.20 148.80 35.89 406.20 580.30 -30.00 406.20 580.30 -30.00
Deferred Tax -27.00 -6.40 321.88 -199.20 -9.00 2113.33 -199.20 -9.00 2113.33
PAT 582.50 394.80 47.54 1157.40 1615.10 -28.34 1157.40 1615.10 -28.34
Equity 50.00 50.00 0.00 50.00 50.00 0.00 50.00 50.00 0.00
PBIDTM(%) 21.34 15.15 40.85 17.16 16.92 1.43 17.16 16.92 1.43

Astrazeneca Pharma I Share Price

8558.50 33.40 (0.39%)
17-Apr-2026 11:28 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1680.80
Dr. Reddys Lab 1222.65
Cipla 1238.70
Zydus Lifesciences 945.60
Lupin 2319.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×